We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Hutchmed (china) Limited | LSE:HCM | London | Ordinary Share | KYG4672N1198 | ORD USD0.10 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 8.00 | 2.82% | 292.00 | 9,826 | 16:35:07 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 288.00 | 290.00 | 292.00 | 286.00 | 286.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | USD 838M | USD 100.78M | USD - | - | 2.47B |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:35:07 | UT | 1 | 292.00 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 05/7/2024 | 19:08 | ALNC |  IN BRIEF: Hutchmed's tazemetostat given priority review in China |
| 04/7/2024 | 07:00 | UK RNS | Hutchmed (China) Limited NDA Acceptance in China for Tazemetostat |
| 28/6/2024 | 12:35 | UK RNS | Hutchmed (China) Limited Overseas Regulatory Announcement: Form F-3 Filing |
| 28/6/2024 | 09:30 | UK RNS | Hutchmed (China) Limited Blocklisting Six Monthly Return |
| 28/6/2024 | 09:30 | UK RNS | Hutchmed (China) Limited Total Voting Rights |
| 26/6/2024 | 09:30 | UK RNS | Hutchmed (China) Limited HUTCHMED to Announce 2024 HY Financial Results |
| 24/6/2024 | 10:30 | UK RNS | Hutchmed (China) Limited Save the Date: HUTCHMED to Present R&D Updates |
| 24/6/2024 | 10:00 | ALNC | IN BRIEF: Hutchmed China notes Takeda obtains EU approval for Fruzaqla |
| 24/6/2024 | 07:00 | UK RNS | Hutchmed (China) Limited European Commission Approval for FRUZAQLA |
| 17/6/2024 | 10:32 | ALNC | Hutchmed celebrates "promising" results for sovleplenib in China |
Hutchmed (china) (HCM) Share Charts1 Year Hutchmed (china) Chart |
|
1 Month Hutchmed (china) Chart |
Intraday Hutchmed (china) Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 12/7/2024 | 07:35 | (Chi-Med)Hutchinson China Meditech Limited | 4,059 |
| 25/3/2022 | 17:25 | Hutchison Chi-Med (HCM) One to Watch | 3 |
| 23/7/2018 | 10:55 | Hutchison Chi-Med (HCM) One to Watch on Monday | 1 |
| 13/6/2017 | 07:54 | Hutchison China Meditech- CHARTS AND DISCUSSION | 74 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2024-07-26 15:35:07 | 292.00 | 1 | 2.92 | UT |
| 2024-07-26 15:29:36 | 290.00 | 74 | 214.60 | AT |
| 2024-07-26 15:28:08 | 290.00 | 56 | 162.40 | AT |
| 2024-07-26 15:12:49 | 287.00 | 1 | 2.87 | AT |
| 2024-07-26 15:12:25 | 287.00 | 1 | 2.87 | O |
| Top Posts |
|---|
Posted at 26/7/2024 09:20 by Hutchmed (china) Daily Update Hutchmed (china) Limited is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker HCM. The last closing price for Hutchmed (china) was 284p.Hutchmed (china) currently has 871,256,270 shares in issue. The market capitalisation of Hutchmed (china) is -. This morning HCM shares opened at 286p |
Posted at 12/7/2024 07:35 by 1jat It seems that Goldman is in at CKHH and its reviews are proving a little leaky,Two stories in two days about the European Three mobile telecoms businesses and a second about CK Infrastructure. When they get to HCM it will be no surprise if they suggest M&A with other China biotech (I would not expect HCM to be the buyer as that would not generate immediate gains for CKHH). They should be having these discussions about reaising SH value from time to time. IMO CKHH has incubated HCM and may decide it does not have the resources/appetite to take it much further or the ability as a Board to oversee this specialist investment and therefore seeks to dilute its ownership. If they can get a proposal above hk$50 they will be obliged to seriously consider it. CK deals have often involved a mix of cash and listed shares followed by sell downs (eg recent mobile mast deal in Europe). No certainty of a deal emerging, but I feel there is change coming at CKHH and HCM may not be untouched by it. |
Posted at 04/7/2024 02:05 by lauders Some more good news: Thursday, July 4, 2024 - HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review StatusOne day the market may start to like the news-flow from HCM! |
Posted at 25/6/2024 08:13 by lauders That was yesterday danmart2, although you wouldn't think it from the price reaction. Perhaps there will be a delayed reaction later this week! Given that HCM are on 3x different exchanges you would struggle to wonder why though! |
Posted at 13/6/2024 10:34 by lauders Deadly dull here and drifting. Good we may be about to break 300p again but we need some decent news to get things going. Never seems to arrive and if something good appears is sold off. Come on HCM give us something to cheer about please! |
Posted at 10/5/2024 07:50 by 1jat LaudersThe sales report from Takeda was IMO a very positive one. They reported FY sales of 10.1bn JPY which is approx $65m, with 15m in 2023, that means Pts signed up for $50m in Q1. They are still building the book and have not reached a steady state when new patients are matched by patients coming off the medication. The $50m is approximately adding a net $5m of new sales each month which adds $30m to revenue each quarter in the short term and then the increment will start to tail off as equilibrium is reached. The maths suggests a likely sales trajectory in the US for 2024 Q/ly sales of 50 80 110 140 which totals $380m. We can watch that develop with the HY results at the end of July, but I would be hopeful that Takeda generates $350m of US revenue this year which will bring HCM $50 of royalty payments. EU approval should come in July with sales in the higher volume but maybe price limited markets following…..TH Japan approval around the end of the year with sales starting in 2025. Other markets to follow using these approvals as a base. I can see HCM getting $150-200m in royalty payments in 2026 which will last for a few years. |
Posted at 09/5/2024 09:33 by lauders Wonder why the rise today? Could it be Takeda related? Sales of Fruzaqla.Doubt it is related to the news yesterday: Hong Kong, Shanghai & Florham Park, NJ - Wednesday, May 8, 2024: HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM: HCM, HKEX: 13) today announces that Dr Renu Bhatia is appointed as an Independent Non-executive Director and a member of Technical Committee of the Company with effect from May 13, 2024. Interesting to see she is the chairman of the Listing Committee of The Stock Exchange of Hong Kong Limited though. |
Posted at 14/3/2024 06:43 by nerdofsteel Excellent share price performance and I admit I sold close to the bottom after years of frustration although did buy 3NVDL on Jan 2nd which is a 3x Nvidia Leveraged ETF so have done extremely well there. I will put some of my profits back into Hutchmed shortly. |
Posted at 03/2/2024 00:47 by lauders More positive news yesterday and no positive impact on the share price. HCM really are in a rut at the moment. Thought 2024 was going to be better, but still 11 months to go. |
Posted at 30/1/2024 05:03 by lauders Some good news from HCM today.Hong Kong, Shanghai & Florham Park, NJ — Tuesday, January 30, 2024: HUTCHMED (China) Limited (Nasdaq/AIM:H Will it be enough to make the share price + for once? Currently DOWN in HK by 1.88%! |
Posted at 14/11/2022 06:58 by lauders Nearly +20% in HK now! Come on HCM share price at least match that! |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
